
-
Russia says claims over annexed Ukraine regions key to peace
-
Austrian climber dies on Nepal mountain
-
Fires rage 2 days after Iran port blast killed 46
-
Palestinian official tells ICJ Israel using aid blockage as 'weapon of war'
-
France arrests 25 in police raids after prison attacks
-
Kim Kardashian's next star turn is in a Paris courtroom
-
Syria group says military chief arrested in UAE
-
Anger in Indian Kashmir at demolitions and detentions
-
Italy bank merger wave heats up as Mediobanca eyes Banca Generali
-
Putin critic Johann Wadephul, Germany's incoming foreign minister
-
Cardinals expected to pick conclave date to elect new pope
-
French mosque murder suspect arrested in Italy
-
China says on 'right side of history' in trade standoff with US
-
Stock markets mostly rise as investors eye trade talks
-
Fires rage 2 days after Iran port blast killed 40
-
Yemen's Huthi rebel media says 68 killed in US strikes on migrant centre
-
Man rescued from Mount Fuji twice in one week: reports
-
Canada votes for new government to take on Trump
-
Top UN court to open hearings on Israel's aid obligation to Palestinians
-
Philippines denies 'irresponsible' Chinese report on disputed reef
-
T'Wolves win to push Lakers to brink, Celtics, Knicks and Pacers win
-
Myanmar marks month of misery since historic quake
-
South Korea's SK Telecom begins SIM card replacement after data breach
-
Women's flag football explodes in US as 2028 Olympics beckon
-
'Hunger breaks everything': desperate Gazans scramble for food
-
Suspect charged with murder in Canada car attack that killed 11
-
Lost to history: Myanmar heritage falls victim to quake
-
Romania far-right rides TikTok wave in election re-run
-
Trial begins in Paris over 2016 gunpoint robbery of Kim Kardashian
-
Trump thinks Zelensky ready to give up Crimea to Russia
-
North Korea confirms troop deployment to Russia's Kursk
-
Romania presidential election re-run under Trump shadow
-
Asian markets mixed as investors eye trade talks
-
T'Wolves push Lakers to brink of elimination, Celtics and Knicks win
-
Suspect charged with murder in Canada car attack that left 11 dead
-
Smart driving new front in China car wars despite fatal crash
-
Cardinals set to pick conclave date to elect new pope
-
Miami's unbeaten MLS run ends after Dallas comeback
-
After 100 days in office, Trump voters still back US president
-
US anti-disinformation guardrails fall in Trump's first 100 days
-
Dick Barnett, two-time NBA champ with Knicks, dies at 88
-
PSG hope to have Dembele firing for Arsenal Champions League showdown
-
Arteta faces Champions League showdown with mentor Luis Enrique
-
Niemann wins LIV Mexico City to secure US Open berth
-
Slot plots more Liverpool glory after Premier League triumph
-
Novak and Griffin win PGA pairs event for first tour titles
-
Sichuan Week, China Pavilion at Expo 2025 Osaka, Kansai, Japan Kicks off Today, Showcasing Splendid Bashu Culture
-
Primary Hydrogen Engages Veteran Landman to Support U.S. Expansion
-
Q2 Metals Extends Mineralized Zone Strike Length to 1.5 Kilometres and Concludes the 2025 Winter Program at the Cisco Lithium Project in Quebec, Canada
-
Empire Metals Limited - Extensive High-Grade Titanium Zones Confirmed

Hemogenyx Pharmaceuticals PLC Announces Final Results
LONDON, UNITED KINGDOM / ACCESS Newswire / April 28, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces its final audited results for the year ended 31 December 2024. The Annual Report is available to view on the Company's website at https://hemogenyx.com/.
Key Highlights
The Company commenced Phase I clinical trials of its HG-CT-1 product candidate.
Continuing development of Chimeric Bait Receptor antiviral/biodefence platform, which gained attention at major conferences.
Successfully raised £3.9 million (before expenses) through the allotment and issue of new ordinary shares during the year ended 31 December 2024, and a further £1.3 million in early 2025.
Fuller details of these developments are contained in the full, unedited text of the final results for the year ended 31 December 2024 below.
http://www.rns-pdf.londonstockexchange.com/rns/3187G_1-2025-4-25.pdf
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
L.Harper--AMWN